Facilitating the Behavioral Treatment of Cannabis Use Disorder
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Cannabis use disorders remain a significant public health problem. The pharmacological
facilitation of behavioral treatment represents a promising strategy for addressing
disordered cannabis use. Cannabis use disorders are recognized to be associated with various
vulnerabilities that complicate the course of treatment and that may be amenable to glutamate
modulators. The purpose of this single blind open-label trial is to test the feasibility of
administering glutamate modulators in conjunction with motivational enhancement therapy (MET)
and mindfulness based relapse prevention (MBRP) for cannabis use disorders.